Vesicular stomatitis virus (VSV), in the family Rhabdoviridaeis, is a non-segmented, negative-strand RNA virus with inherent oncolytic virus qualities which is more susceptible to infect cancer cells that contain antiviral responses induced by type I interferon pathways. The characteristics of VSV like an easily manipulated genome, the relative independence of a receptor or cell cycle, the cytoplasmic replication without risk of host-cell transformation and lack of pre-existing immunity in humans make it an especially potent and a highly promising agent for the treatment of cancer. To enhance the safety of oncolytic VSV while increasing the capacity for therapeutic transgenes, Creative Biolabs has established a comprehensive platform called OncoVirapy™ for providing oncolytic virus development service. By virtue of OncoVirapy™, we are able to design, engineer and generate the most efficacious oncolytic vesicular stomatitis viral products.
Oncolytic virus vesicular stomatitis virus with a small genome encodes five major proteins: the G protein (G) which mediates viral attachment to the LDL receptor (LDLR) or the LDLR family member that presents on the host cell enables viral entry. The large protein (L) is encoded by half the genome and combines with the phosphoprotein to catalyze replication of the mRNA. Others are Phosphoprotein, nucleoprotein and the matrix protein (M). Several approaches can be applied for viral reconstruction, such as the mutations of M protein or G protein for cancer suppressors gene, suicide gene or immunomodulation expression. Also, the miRNA targets and foreign glycoproteins gene can be inserted for viral tropism select-ability. These designed oncolytic vesicular stomatitis viruses have been found to have oncolytic properties. And it has proven to be effective against a variety of tumor entities such as malignant glioma, hepatocellular carcinoma, prostate cancer, and ovarian carcinoma.
Creative Biolabs has developed an all-sided OncoVirapy™ platform to offer customized, standardized and high-quality oncolytic vesicular stomatitis virus expressing antibody for clients globally. The immune-check points protein (CTLA4, PD-1), the cytokine/chemokine (IL-12, GM-SCF) and the siRNA and shRNA (siNotch1, shSurvivin, shMPP1, and shVEGF) can be expressed to a multifunctional oncolytic virus. The antisense sequence (miRT) including but not limited to miR-122T which is specific to hepatocellular carcinoma (HCC) cells, miR-182T which is specific to uveal melanoma (UM) cells can change the selectivity of viral replication. And the glycoproteins can be replaced by designed foreign glycoproteins for different viral tropism. We also provide oncolytic vesicular stomatitis virus based on customer demand. The proof-of-concept validation study for the oncolytic virus is also provided. With the increasing experience and knowledge of VSV system, coupled with the OncoVirapy™ platform, Creative Biolabs commits to developing efficacious oncolytic vesicular stomatitis virus. Please don’t hesitate to contact us for more information and quotation.
Please feel free to contact us for a quote and further discussion with our scientists.